# Epizyme, Inc.

Epizyme, Inc. is a company headquartered in Cambridge, MA, United States.

## Company overview

- **Legal name:** Epizyme, Inc.
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Cambridge, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001571498

## About

Epizyme, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001571498, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2022-03-01, it reported annual revenue of USD 37,427,000; net income of USD -251,122,000; total assets of USD 289,000,000 for the fiscal period ended 2021-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $37.4M (USD 37,427,000)
- **Net income:** -$251.1M (USD -251,122,000)
- **Total assets:** $289.0M (USD 289,000,000)
- **Cash and equivalents:** $98.3M (USD 98,336,000)
- **Operating cash flow:** -$226.9M (USD -226,853,000)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $15.8M (USD 15,762,000)
- **Net income:** -$231.7M (USD -231,694,000)
- **Total assets:** $473.6M (USD 473,573,000)
- **Cash and equivalents:** $168.2M (USD 168,215,000)
- **Operating cash flow:** -$206.3M (USD -206,336,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $23.8M (USD 23,800,000)
- **Net income:** -$170.3M (USD -170,295,000)
- **Total assets:** $424.6M (USD 424,589,000)
- **Cash and equivalents:** $139.5M (USD 139,482,000)
- **Operating cash flow:** -$147.2M (USD -147,168,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $21.7M (USD 21,700,000)
- **Net income:** -$123.6M (USD -123,630,000)
- **Total assets:** $275.5M (USD 275,501,000)
- **Cash and equivalents:** $86.7M (USD 86,671,000)
- **Operating cash flow:** -$121.6M (USD -121,600,000)

## Recent SEC filings

- Form 8-K — filed 2022-08-12 — period 2022-08-12 — 8-K
- Form 10-Q — filed 2022-08-09 — period 2022-06-30 — 10-Q
- Form 8-K — filed 2022-08-09 — period 2022-08-09 — 8-K
- Form SC 13D — filed 2022-07-07 — SC 13D
- Form 8-K — filed 2022-06-27 — period 2022-06-26 — 8-K
- Form 8-K — filed 2022-05-24 — period 2022-05-20 — 8-K
- Form 8-K — filed 2022-05-19 — period 2022-05-17 — 8-K
- Form 10-Q — filed 2022-05-10 — period 2022-03-31 — 10-Q
- Form 8-K — filed 2022-05-10 — period 2022-05-10 — 8-K
- Form 8-K — filed 2022-04-06 — period 2022-04-06 — 8-K
- Form DEF 14A — filed 2022-03-30 — period 2022-05-17 — DEF 14A
- Form 8-K — filed 2022-03-15 — period 2022-03-11 — 8-K

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/epizyme-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology